These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34423717)

  • 1. Systemic Immunosuppression in Cornea and Ocular Surface Disorders: A Ready Reckoner for Ophthalmologists.
    Kate A; Basu S
    Semin Ophthalmol; 2022 Apr; 37(3):330-344. PubMed ID: 34423717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.
    Miserocchi E; Baltatzis S; Roque MR; Ahmed AR; Foster CS
    Ophthalmology; 2002 Jan; 109(1):111-8. PubMed ID: 11772589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of topical and systemic immunosuppression in aqueous-deficient dry eye disease.
    Kate A; Shanbhag SS; Donthineni PR; Amescua G; Quinones VLP; Basu S
    Indian J Ophthalmol; 2023 Apr; 71(4):1176-1189. PubMed ID: 37026249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide for ocular inflammatory diseases.
    Pujari SS; Kempen JH; Newcomb CW; Gangaputra S; Daniel E; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Foster CS
    Ophthalmology; 2010 Feb; 117(2):356-65. PubMed ID: 19969366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Systemic Mycophenolate Mofetil Therapy in Ocular Surface Inflammatory Pathologies at the Initiative and Responsibility of the Ophthalmologist.
    Furundaoturan O; Akçay P; Selver OB
    Middle East Afr J Ophthalmol; 2022; 29(4):209-215. PubMed ID: 38162558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limbal stem cell transplantation: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2008; 8(7):1-58. PubMed ID: 23074512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidisciplinary management of auto-immune ocular diseases in adult patients by ophthalmologists and rheumatologists.
    Van Bentum RE; Van den Berg JM; Wolf SE; Van der Bijl J; Tan HS; Verbraak FD; van der Horst-Bruinsma IE
    Acta Ophthalmol; 2021 Mar; 99(2):e164-e170. PubMed ID: 32749781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic cicatrizing conjunctivitis: A review of the differential diagnosis and an algorithmic approach to management.
    Vazirani J; Donthineni PR; Goel S; Sane SS; Mahuvakar S; Narang P; Shanbhag SS; Basu S
    Indian J Ophthalmol; 2020 Nov; 68(11):2349-2355. PubMed ID: 33120615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular cicatricial pemphigoid: case report.
    Louie TD
    J Am Optom Assoc; 1998 Mar; 69(3):153-60. PubMed ID: 9553330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].
    Meyer-ter-Vehn T; Schmidt E; Zillikens D; Geerling G
    Ophthalmologe; 2008 Apr; 105(4):405-19. PubMed ID: 18392628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular mucous membrane pemphigoid: novel treatment strategies.
    Jabbour S; Phylactou M; Ahmad S
    Curr Opin Allergy Clin Immunol; 2021 Oct; 21(5):486-492. PubMed ID: 34269741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate for ocular inflammatory diseases.
    Gangaputra S; Newcomb CW; Liesegang TL; Kaçmaz RO; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Kempen JH;
    Ophthalmology; 2009 Nov; 116(11):2188-98.e1. PubMed ID: 19748676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case series of ocular involvement in bullous pemphigoid: clinical features, management, and outcomes.
    Kate A; Shanbhag S; Donthineni PR; Basu S
    F1000Res; 2021; 10():1201. PubMed ID: 35136583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.
    Saw VP; Dart JK; Rauz S; Ramsay A; Bunce C; Xing W; Maddison PG; Phillips M
    Ophthalmology; 2008 Feb; 115(2):253-261.e1. PubMed ID: 17655931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate therapy for ocular cicatricial pemphigoid.
    McCluskey P; Chang JH; Singh R; Wakefield D
    Ophthalmology; 2004 Apr; 111(4):796-801. PubMed ID: 15051215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
    Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
    Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular Cicatricial Pemphigoid - a Retrospective Study].
    Szabó E; Palos M; Skalická P
    Cesk Slov Oftalmol; 2016 Feb; 72(1):283-92. PubMed ID: 27041284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of buccal mucosal grafting for patients with medically controlled ocular cicatricial pemphigoid.
    Shore JW; Foster CS; Westfall CT; Rubin PA
    Ophthalmology; 1992 Mar; 99(3):383-95. PubMed ID: 1565450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of systemic targeted immunosuppressive therapy on ocular surface.
    Mukhtar S; Jhanji V
    Curr Opin Ophthalmol; 2022 Jul; 33(4):311-317. PubMed ID: 35779055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of mucous membrane pemphigoid with ocular involvement in young patients.
    Rauz S; Maddison PG; Dart JK
    Ophthalmology; 2005 Jul; 112(7):1268-74. PubMed ID: 15921743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.